Zacks.com on MSN1h
Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLCMerck MRK announced that the FDA has granted breakthrough therapy designation (BTD) to sacituzumab tirumotecan (sac-TMT) for ...
Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...
By inferring proliferation rates from single-cell genomics, SPRINTER enhances understanding of tumor evolution and identifies ...
A medical expert discusses how Lambert-Eaton myasthenic syndrome is closely linked to small cell lung cancer, the challenges ...
Precision medicine in the context of lung cancer represents a transformative approach that integrates prevention, diagnosis, and treatment tailored to individual patient differences. This field ...
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...
A study from the University of Michigan Health Rogel Cancer Center may have—at last—cracked the cold case of immunotherapy ...
The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...
Merck's (MRK) antibody drug conjugate sac-TMT has received FDA Breakthrough Therapy designation for the treatment of EGFR-mutated lung cancer. Read more here.
The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed ...
This page includes links to articles highlighting the top lung cancer research published on Cancer Therapy Advisor in 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback